Top Page
HeraMED Ltd.
(Frankfurt:HMD)
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
HeraMED Ltd. Business Overview & Revenue Model
HeraMED Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 225.49K | 402.90K | ― | ― | ― |
| Gross Profit | 79.75K | 241.94K | ― | ― | ― |
| EBITDA | -3.35M | -3.97M | ― | ― | ― |
| Net Income | -3.40M | -4.50M | ― | ― | ― |
Balance Sheet | |||||
| Total Assets | 2.78M | 2.01M | ― | ― | ― |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 723.29K | ― | ― | ― |
| Total Debt | 815.96K | 209.37K | ― | ― | ― |
| Total Liabilities | 1.06M | 1.55M | ― | ― | ― |
| Stockholders Equity | 1.72M | 466.70K | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -2.98M | -3.80M | ― | ― | ― |
| Operating Cash Flow | -2.98M | -3.89M | ― | ― | ― |
| Investing Cash Flow | 0.00 | -1.39K | ― | ― | ― |
| Financing Cash Flow | 4.26M | 2.02M | ― | ― | ― |
HeraMED Ltd. Technical Analysis
HeraMED Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $8.19B | 160.20 | 14.52% | ― | 55.85% | 893.42% | |
64 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
58 Neutral | $804.83M | 135.47 | 8.30% | ― | 39.19% | 273.91% | |
49 Neutral | AU$2.53B | 3.19 | -57.47% | 2.77% | 36.73% | 13.67% | |
48 Neutral | AU$49.98M | ― | -8.08% | ― | -5.62% | -225.71% | |
47 Neutral | AU$41.35M | ― | -19.31% | ― | 72.25% | 43.66% | |
45 Neutral | AU$9.63M | ― | -321.94% | ― | -39.97% | 55.29% |
HeraMED Ltd. Corporate Events
HeraMED Limited has announced the scheduling of its Annual General Meeting (AGM) for 29 May 2025, to be held at BDO Offices in Docklands, VIC. The company emphasizes the importance of shareholder participation, encouraging votes to be submitted by proxy if attendance is not possible. This meeting is significant for stakeholders as it will address resolutions affecting shareholding, with all resolutions to be decided by a poll.
HeraMED Limited has announced that its Annual General Meeting will take place on May 29, 2025, and has set April 14, 2025, as the deadline for director nominations. This announcement underscores the company’s ongoing governance activities and provides stakeholders with an opportunity to influence its strategic direction through board elections.
HeraMED Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Anoushka Gungadin will present the company’s advancements in digital maternity care. This presentation underscores HeraMED’s commitment to revolutionizing the maternity care industry and highlights its strategic efforts to engage with stakeholders and investors, potentially enhancing its market position and influence in the healthcare sector.
HeraMED Ltd. has released its corporate governance statement for the financial year ending December 31, 2024, which has been approved by the board as of February 28, 2025. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, indicating that the company has followed these guidelines throughout the reporting period. This release underscores HeraMED’s commitment to transparency and accountability, potentially strengthening its position in the market and reassuring stakeholders of its governance practices.
HeraMED Ltd. has released its annual report for the year ending December 31, 2024, highlighting its financial performance and strategic initiatives. The report provides insights into the company’s operations, including its commitment to expanding its market presence and improving shareholder value, which may influence its industry positioning and stakeholder interests.
HeraMED Ltd. reported a 20.6% decline in revenues for the year ending December 31, 2024, with a net loss of $5,490,578, marking a 19% improvement over the previous year’s loss. Despite the financial downturn, the company did not declare any dividends, and its net tangible assets per ordinary security increased to 0.23 cents, indicating a potential strengthening of its asset base.
HeraMED Limited has entered into a strategic collaboration with Garmin Health to integrate Garmin smartwatch data into its HeraCARE platform, enhancing remote pregnancy monitoring. This partnership will expand the range of health data available to expectant mothers, improve continuous monitoring capabilities, and support women’s health research. The collaboration is expected to enhance HeraMED’s industry positioning by providing a more holistic view of maternal health, aligning with its ‘data-as-an-asset’ strategy.
HeraMED Ltd. has released a presentation highlighting its commitment to leading the digital transformation of maternity care. The announcement underlines the company’s strategic positioning within the healthcare industry, showcasing its FDA-approved solutions aimed at enhancing maternity care services, which could potentially strengthen its market position and stakeholder confidence.
HeraMED Ltd. has announced a change in the director’s interest, revealing that Anoushka Gungadin, a director of the company, has acquired 15,800,000 performance rights. These rights are tied to specific share price premiums and accumulated user metrics on the HeraCARE platform, which suggests a strategic focus on enhancing shareholder value and platform growth. This change could potentially impact HeraMED’s operational strategies and stakeholder interests by aligning director incentives with the company’s performance goals, thereby reinforcing its commitment to achieving key financial and user engagement targets.
HeraMED Ltd. announced the issuance of 15,800,000 unquoted performance rights under an employee incentive scheme. These securities are designed to reward and retain staff, supporting the company’s growth and operational goals. The issuance is part of HeraMED’s strategic efforts to strengthen its workforce and maintain its competitive position in the healthcare technology market.